Deka Bank Deutsche Girozentrale Mirati Therapeutics, Inc. Transaction History

Deka Bank Deutsche Girozentrale

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 01, 2023	SELL	$41.27 - $98.62 $707,367 - $1.69 Million	-17,140 Reduced 46.15%	20,000 $845,000
Q2 2022 Aug 03, 2022	SELL	$39.16 - $88.71 $68,530 - $155,242	-1,750 Reduced 4.5%	37,140 $2.47 Million
Q1 2022 Apr 28, 2022	SELL	$75.82 - $150.97 $45,491 - $90,582	-600 Reduced 1.52%	38,890 $3.28 Million
Q4 2021 Feb 02, 2022	BUY	$132.01 - $190.29 $699,653 - $1.01 Million	5,300 Added 15.5%	39,490 $5.68 Million
Q1 2021 Apr 28, 2021	BUY	$158.92 - $221.61 $1.84 Million - $2.57 Million	11,600 Added 51.35%	34,190 $5.64 Million

Q4 2020 Mar 12, 2021	SELL	$162.05 - $240.27 $803,768 - $1.19 Million	-4,960 Reduced 18.0%	22,590 $4.96 Million
Q3 2020 Oct 29, 2020	BUY	$113.26 - $167.27 $1.6 Million - $2.37 Million	14,150 Added 105.6%	27,550 $4.55 Million
Q2 2020 Aug 04, 2020	BUY	$72.01 - $120.39 $333,046 - $556,803	4,625 Added 52.71%	13,400 $1.53 Million
Q1 2020 May 14, 2020	BUY	$69.78 - $116.21 $612,319 - $1.02 Million	8,775 New	8,775 $722,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.